{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:00:37Z","timestamp":1786993237611,"version":"build-2736575974"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jphs.2026.03.002","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:50:32Z","timestamp":1773391832000},"page":"25-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Viral infection and establishing new therapeutic platforms\u2013 On the occasion of receiving the 16th Setsuro Ebashi award \u2013"],"prefix":"10.1016","volume":"161","author":[{"given":"Yumiko","family":"Imai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2026.03.002_bib1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.jphs.2026.03.002_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jphs.2026.03.002_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cell.2008.02.043","article-title":"Identification of oxidative stress and toll-like receptor 4 signaling as a key pathway of acute lung injury","volume":"133","author":"Imai","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.jphs.2026.03.002_bib4","article-title":"Tocilizumab as a targeted immunomodulatory therapy in the management of severe respiratory illnesses: a multicenter cohort study of COVID-19 patients","volume":"15","author":"Al","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jphs.2026.03.002_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.833174","article-title":"Pulmonary inflammatory response in lethal COVID-19 reveals potential therapeutic targets and drugs in phases III\/IV clinical trials","volume":"13","author":"Lopez-Cortes","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jphs.2026.03.002_bib6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bbalip.2014.08.006","article-title":"Protectins and maresins: new pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome","volume":"1851","author":"Serhan","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jphs.2026.03.002_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.cell.2013.02.027","article-title":"The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza","volume":"153","author":"Morita","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jphs.2026.03.002_bib8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41564-018-0289-1","article-title":"Pulmonary phagocyte-derived NPY controls the pathology of severe influenza virus infection","volume":"4","author":"Fujiwara","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jphs.2026.03.002_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-0716-4615-1_6","article-title":"Applying 3D genome technology in virology research","volume":"2940","author":"Liang","year":"2025","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jphs.2026.03.002_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102660","article-title":"Suv4-20h2 protects against influenza virus infection by suppression of chromatin loop formation","volume":"24","author":"Shiimori","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.jphs.2026.03.002_bib11","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1038\/s41467-021-27097-8","article-title":"ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury","volume":"12","author":"Yamaguchi","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jphs.2026.03.002_bib12","article-title":"Protective role of apelin in a mouse model of post-intensive care syndrome","author":"Imai","year":"2025","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jphs.2026.03.002_bib13","first-page":"416","article-title":"Post-coronavirus disease 2019 syndrome in Japan: an observational study using a medical database","volume":"6","author":"Kinugasa","year":"2023","journal-title":"JMA J"},{"key":"10.1016\/j.jphs.2026.03.002_bib14","first-page":"59","article-title":"AI modeling of severe COVID-19","volume":"40","author":"Kinugasa","year":"2023","journal-title":"Jpn J Respir Care"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861326000150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861326000150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:29:57Z","timestamp":1776814197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861326000150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1347861326000150"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2026.03.002","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral infection and establishing new therapeutic platforms\u2013 On the occasion of receiving the 16th Setsuro Ebashi award \u2013","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2026.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}